title: Genentech's glyco-engineered antibody to succeed Rituxan.
authors.forename: Mark
authors.initials: M
authors.lastname: Ratner
mesh_terms: D000906:Antibodies / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D004345:Drug Industry; D006801:Humans; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D060847:Metabolic Engineering; D000069283:Rituximab; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000906:Antibodies; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab